Transaction DateRecipientSharesTypePriceValue
17th November 2020Management 4 G.P. (2015) Ltd. Pontifax14,400Open or private purchase$50.00$720,000.00
17th November 2020Management 4 G.P. (2015) Ltd. Pontifax6,000Open or private purchase$50.00$300,000.00
17th November 2020Management 4 G.P. (2015) Ltd. Pontifax26,634Open or private purchase$50.00$1,331,700.00
17th November 2020Management 4 G.P. (2015) Ltd. Pontifax12,966Open or private purchase$50.00$648,300.00
30th October 2020Gregory C. Williams625Payment by withholding$2.53$1,581.25
30th October 2020Neil S. Belloff459Payment by withholding$2.53$1,161.27
30th October 2020Neil S. Belloff1,562Exercise of derivative$0.00
30th October 2020Gregory C. Williams1,875Exercise of derivative$0.00
30th July 2020Gregory C. Williams576Payment by withholding$2.84$1,635.84
30th July 2020Neil S. Belloff1,563Exercise of derivative$0.00
Sevion Therapeutics
Sevion Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Ticker: SVOND
Sector: Unknown
Industry: Unknown
SEC Central Index Key (CIK): 1035354
Exchange: None
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $30 M (0%)
Assets, Current: $39 M (-32%)
Property, Plant and Equipment, Net: $165 Th (0%)
Other Assets, Noncurrent: $110 Th (-2%)
Assets: $40 M (-32%)
Long-term Debt, Current Maturities: $5 M (0%)
Accounts Payable, Current: $770 Th (-58%)
Accrued Liabilities, Current: $3 M (0%)
Liabilities, Current: $11 M (-8%)
Long-term Debt, Excluding Current Maturities: $9 M (0%)
Liabilities: $20 M (-13%)
Common Stock, Value, Issued: $403 Th (0%)
Common Stock, Shares, Issued: $40 M (0%)
Additional Paid in Capital, Common Stock: $181 M (3%)
Retained Earnings (Accumulated Deficit): $159 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $13 Th (-27%)
Stockholders' Equity (Parent): $20 M (0%)
Liabilities and Equity: $40 M (-32%)
Research and Development: $4 M (-56%)
General and Administrative Expenses: $4 M (-56%)
Operating Income/Loss: $8 M (-64%)